Smartlab Europe

News

Moderna starts Phase I study of new Covid-19 vaccine candidate

Moderna Inc., a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, announced that the first participants have been dosed in the Phase 2/3 study, called the KidCOVE study, of mRNA-1273, the Company’s vaccine candidate against COVID-19, in children...

AstraZeneca to supply the US with up to half a million additional doses of the potential COVID-19 antibody treatment AZD7442

AstraZeneca has modified an existing agreement with the US Government to supply up to 500,000 additional doses of AZD7442, a long-acting antibody (LAAB) combination which is in late-stage development for the prevention and treatment of COVID-19. Today’s agreement with the...

Tevogen Bio, BioCentriq Partner for COVID T-cell Therapy

Tevogen Bio has entered a partnership with BioCentriq, a New Jersey based cell and gene therapy development and manufacturing center, to support clinical manufacturing of Tevogen’s investigational COVID-19 treatment. Both partners will collaborate at BioCentriq’s state-of-the art GMP facilities to...

Novartis presents positive data from Zolgensma for essential one-time treatment for SMA at MDA virtual conference

Novartis announced new data that reinforce the transformational benefit of Zolgensma (onasemnogene abeparvovec), an essential one-time treatment for spinal muscular atrophy (SMA). The overall safety profile remains favorable following presymptomatic treatment, in the long-term follow-up period from clinical studies...

Roche to acquire multiplex molecular diagnostic solutions provider, GenMark Diagnostics for US$ 1.8 billion

Roche and GenMark Diagnostics announced that they have entered into a definitive merger agreement for Roche to fully acquire GenMark at a price of US$ 24.05 per share in an all-cash transaction. This corresponds to a total transaction value...

Frost & Sullivan sees decentralization critical to success of Indias Covid-19 vaccination campaign

Union government needs to implement multiple innovative ways to make vaccines easily accessible. decentralization of vaccination is paramount for increasing coverage in urban areas and reach rural India. There is a need to adopt strongly consider moving out of...

Biovaxy’s Enters Major Bioproduction Agreement With WuXi Biologics to Synthesize Proteins for Its Sars-CoV-2 Vaccine and Covid-T Immunodiagnostic Programs

BioVaxys Technology Corp., the world leader in haptenized protein vaccines for antiviral and cancer applications, announced today that it has entered into a major bioproduction agreement with WuXi Biologics Limited (“WuXi”), a leading global Contract Development and Research Organization...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate »